Literature DB >> 19220265

Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density.

Christoph Wiesner1, Alice Salzer, Christian Thomas, Claudia Gellermann-Schultes, Rolf Gillitzer, Christian Hampel, Joachim W Thüroff.   

Abstract

OBJECTIVE: To investigate the associations between different overall or topographically restricted lymph node (LN) variables and cancer-specific survival (CSS) after radical cystectomy (RC) and extended LN dissection (LND) with curative intent in patients with LN-positive bladder cancer. PATIENTS AND METHODS: Between 2001 and 2006, 152 patients had RC with standardized extended LND for bladder cancer with curative intent. Patients with positive LNs were stratified according to the median of the LN variables (LNs removed, number of positive LNs, LN density). CSS was related to overall and topographically restricted LN variables, e.g. different levels of LND, and relationships were tested by univariate and multivariate analyses. Level 1 LND comprised the regions of the external and internal iliac LNs and of the obturator LNs, level 2 the templates of common iliac and presacral LNs, and level 3 the para-aortic and paracaval LNs up to the inferior mesenteric artery. The mean (range) follow-up was 22 (1-84) months.
RESULTS: LN metastases were diagnosed in 46 of the 152 patients (30%) with extended LND. In these 46 patients, the median number of removed LNs was 33 (level 1, 15.5; level 2, 9.0; level 3, 7.0), the median number of positive LNs was 3 (1.5, 0.5 and 0.0, respectively) and the median LN density was 0.11 (0.10, 0.02 and 0.0, respectively). The CSS was 76% at 1 year and 23% at 3 years. There were significant correlations between the 3-year CSS and the overall LN density (< or =0.11 vs >0.11; 34% vs 8%, P = 0.008), and the total number of positive LNs (< or =3 vs >3; 33% vs 8%; P = 0.05). Overall LN density (hazard ratio 0.33, 95% confidence interval 0.15-0.72; P = 0.006) was an independent predictor for CSS in multivariate analysis. CONCLUSIONS Overall LN density is an independent predictor of survival after RC and extended LND with curative intent. Evaluation of topographically restricted LN positivity and density for different regions and levels of LND does not improve the prediction of CSS compared with overall LN positivity and density. A low incidence of level 3 LN positivity questions the clinical relevance of removing para-aortic and paracaval LNs. However, our data need to be confirmed by a prospective randomized trial.

Entities:  

Mesh:

Year:  2009        PMID: 19220265     DOI: 10.1111/j.1464-410X.2009.08403.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  24 in total

Review 1.  [When should systemic chemotherapy be used for urinary bladder carcinoma?].

Authors:  C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

Review 3.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

Review 4.  [Lymphadenectomy for bladder cancer: current status and controversies].

Authors:  T Metzger; G N Thalmann; P Zehnder
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

5.  [Diagnostic work-up and treatment of bladder cancer: current developments].

Authors:  C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

6.  [Continent urinary diversion following anterior exenteration].

Authors:  R Stein; M G Kamal; P Rubenwolf; A Großmann; C Thomas; J W Thüroff
Journal:  Urologe A       Date:  2015-03       Impact factor: 0.639

7.  Role of pelvic lymphadenectomy in the treatment of bladder cancer: a mini review.

Authors:  Ja Hyeon Ku
Journal:  Korean J Urol       Date:  2010-06-21

8.  [Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer].

Authors:  C-H Ohlmann; M De Santis
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

9.  Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent.

Authors:  Thomas Horn; Sebastian C Schmid; Anna K Seitz; Jessica Grab; Petra Wolf; Bernhard Haller; Margitta Retz; Tobias Maurer; Michael Autenrieth; Hubert R Kübler; Jürgen E Gschwend
Journal:  World J Urol       Date:  2014-07-10       Impact factor: 4.226

10.  The number of nodes removed as well as the template of the dissection is independently correlated to cancer-specific survival after radical cystectomy for muscle-invasive bladder cancer.

Authors:  Eugenio Brunocilla; Remigio Pernetti; Riccardo Schiavina; Marco Borghesi; Valerio Vagnoni; Giovanni Christian Rocca; Filippo Borgatti; Sergio Concetti; Giuseppe Martorana
Journal:  Int Urol Nephrol       Date:  2013-05-12       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.